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Abstract
Background: Despite the benefits of highly active antitretroviral therapy (HAART) for
suppressing viral replication in HIV infection, virus persists and rebounds during treatment
interruption (TI). This study explored whether HAART intensification with Remune™ vaccination
before TI can boost HIV-1-specific immunity, leading to improved control of viremia off HAART.
Methods: Ten chronically HIV-infected adults were enrolled in this proof of concept study. After
a 6-month HAART intensification phase with didanosine, hydroxyurea, granulocyte-macrophage
colony-stimulating factor, (GM-CSF), and a first dose of Remune™ (HIV-1 Immunogen), HAART
was discontinued. Patients continued to receive Remune™ every 3 months until the end of study.
HAART was restarted if viral load did not fall below 50,000 copies/ml of plasma within 3 months
or if CD4+ counts decreased to <200 cells/mm3. HIV-specific immunity was monitored with the
interferon-γ (IFN-γ) ELISPOT assay.
Results: All subjects experienced viral rebound during TIs. Although the magnitude and breadth
of HIV-specific responses to HLA-restricted optimal peptide panels and Gag p55 peptide pools
increased and viral load decreased by 0.44 log10 units from TI#1 to TI#2, no significant correlations
between these parameters were observed. The patients spent 50.4% of their 36 months follow up
off HAART.
Conclusion: Stopping HAART in this vaccinated population induced immune responses that
persisted after therapy was restarted. Induction of HIV-specific immunity beyond IFN-γ secretion
may be contributing to better control of viremia during subsequent TIs allowing for long periods
off HAART.
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The introduction of highly active antiretroviral therapy
(HAART) to the management of patients infected with
HIV has significantly decreased mortality and morbidity
[1]. Although HAART suppresses HIV replication in a sig-
nificant proportion of HIV infected individuals, it is not
able to eradicate viral infection [2,3]. Serious side effects
and emergence of drug resistant virus provide the impetus
to explore alternatives to continuous HAART [4,5].
HIV specific CD8+ T cells contribute to the control of HIV
replication. The strongest evidence supporting this comes
from an animal model of HIV infection, macaques
infected with the simian immunodeficiency virus (SIV). In
SIV infected macaques CD8+ T cell depletion results in
increased viral load, which returns to pre-treatment values
when CD8+ T cells reemerge [6]. Several other observa-
tions support a role for CD8+ T cells in control of HIV.
These include viral escape from the CTL responses [7-10],
the temporal association between decline in viral load
and the emergence of CTL responses in HIV primary infec-
tion (PI) [11,12], the association of certain major histo-
compatibility complex (MHC) class I alleles and
heterozygosity at loci coding for these alleles with rate of
HIV disease progression [13,14] and the association
between HIV-specific CD8+ proliferative responses and
long term non progressor status [15]. Initiation of HAART
in the chronic phase of infection generally results in a
decline in the breadth and magnitude of the HIV-specific
responses in association with viral load control [16,17].
In order to boost HIV-specific immunity and limit expo-
sure to antiretroviral drugs, treatment interruptions (TI)
are being investigated. The rationale behind TI in HIV
infection is that stopping treatment allows reemergence of
autologous virus, which will boost virus specific immu-
nity that can contribute to subsequent viral load control.
In subjects who start HAART in acute HIV infection, the
breadth and magnitude of HIV-specific immune
responses is compromised compared with that seen later
in infection [18-20]. In these individuals, TIs have been
used after a period on HAART to expand HIV-specific
immunity [21]. This strategy of early initiation of HAART
followed by a controlled TI increased HIV-specific immu-
nity and transiently suppressed viral replication.
TI performed in the setting of chronic infection has been
largely unsuccessful in stimulating immunity that con-
trols viremia [22-24]. For this reason, therapeutic vaccina-
tion and immunomodulatory therapies, which boost
HIV-specific immunity are currently being investigated for
HAART treated chronically HIV-infected patients prior to
TI to determine whether they induce HIV-specific immu-
nity that improves viral load control off therapy. The use
of therapeutic HIV immunization (Remune™ – HIV-1
Immunogen) in chronic HIV infection to induce HIV-spe-
cific lymphoproliferative responses (LPR) is well docu-
mented. [25-28].
We present results on within-subject changes in HIV-spe-
cific immunity induced in HIV infected patients (n = 10)
in the chronic phase of infection who underwent therapy
intensification and vaccination with Remune™ before
multiple rounds of TI. We observed that the magnitude
and breadth of HIV-specific responses detected in IFN-γ
ELISPOT and intracellular cytokine secretion assays
increased from on treatment time points pre-TI#1 to pre-
TI#2. However, this increase in HIV-specific immune
response did not correlate with the decrease in the viral
load plateau seen during TI#1 to that seen during TI#2.
Although our results show that HAART intensification
and Remune™ vaccination were able to reduce and sustain
lower VL plateau during consecutive cycles of TI, this
reduction did not correlate with increases in HIV-specific
responses measured.
Methods
Patient population and study design
Ten healthy HIV infected adults in the chronic phase of
infection were enrolled in March 2000 in this proof of
concept trial. The research conformed with all ethical
guidelines of the authors' institutions and with human
experimentation guidelines of the US Department of
Health and Human Services. All participants signed
informed consent. At the time of enrollment, the 10
patients had a median age of 41 (range 36 to 51) years,
had been on antiretroviral therapy for a median of 4.6
(range 1.4 to11) years and had been on HAART for a
median of 2.7 (range 1.4 to 3.8) years, had HIV viral loads
(VL) <50 copies/ml for a median of 2 (range 0.5 to 2.1)
years, and median CD4+ T-cell counts of 385 (range 230
to 990) cells/mm3 (Table 1).
The treatment schedule included a 6-month HAART
intensification phase, during which didanosine (ddI) and
hydroxyurea (HU) were added to the existing regimen for
the first 5 months and granulocyte-macrophage colony-
stimulating factor (GM-CSF) for the first 3 months.
Remune™ (10 units of p24 antigen – 100 μg total protein,
in Incomplete Freund's Adjuvant) was given at month 5 of
the treatment intensification phase when HU was
stopped. All 10 patients completed another month of
therapy intensification with ddI and were vaccinated with
Remune™ at three-month intervals until the end of study.
Patients were monitored for 36 months after the first TI.
Blood samples were obtained at baseline, month 3, 6, of
the HAART intensification phase, and every 3 months for
36 months thereafter for virological and immunological
assessments. HAART and HU were resumed if VL did not
decrease to <50 000 copies within 3 months or if thePage 2 of 12
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again interrupted when viral load was <50 HIV-1 RNA
copies/ml and CD4+ counts were >200 cells/mm3 meas-
ured on two occasions one month apart.
HIV quantification
Plasma viremia was determined using the Roche Amplicor
Assay (Roche Diagnostics, Mississauga, Ontario, Canada)
with a detection limit of 500 HIV-1 RNA copies/ml of
plasma. Samples falling below the detection limit were
retested with the ultrasensitive method (Ultradirect;
Roche Diagnostics) with a detection limit of 50 HIV-1
RNA copies/ml.
HLA typing
Genomic DNA for molecular HLA typing was prepared
from Epstein-Barr virus (EBV)-transformed B cell lines
using the QIAamp DNA blood kit (Qiagen, Mississauga,
Ontario, Canada). Each patient was typed for HLA class I
alleles using 95 primer sets amplifying defined MHC class
I alleles (ABC SSP Unitray; PelFreez Clinical Systems,
Brown Deer, Wisconsin, USA) [29]
Cells and Peptide Selection
Peripheral blood mononuclear cells (PBMC) were iso-
lated from blood collected in acid citrate dextrose antico-
agulant at each study visit by density gradient
centrifugation (Ficoll-Paque, Pharmacia, Upsala, Sweden)
and frozen in 90% fetal calf serum (GIBCO BRL Life Tech-
nologies, Burlington, Ontario, Canada), 10% dimethyl
sulfoxide (DMSO, Sigma, St. Louis MO). The HIV
epitopes used for PBMC stimulation were chosen from
the Los Alamos HIV Molecular Immunology Database
[30]. Optimal peptides of 8 to 10 aa in length restricted to
the MHC class I alleles expressed by the individuals being
tested were synthesized to greater than 85% purity by
solid phase synthesis using F-MOC chemistry (Sheldon
Biotechnology Center, Montreal, Quebec, Canada).
Twenty-mer peptides corresponding to HIV Gag p55 were
obtained from the National Institute of Biological Stand-
ards and Controls (Potters Bar Hertz, UK). These were
organized into pools containing peptides corresponding
to HIV Gag p17, p24 and p15. Each peptide in these pools
was present at a final concentration of 2.0 μg/ml. In addi-
tion, MHC restricted EBV- or cytomegalovirus (CMV)-
derived 8- to 10-mer optimal peptides were also synthe-
sized as described above and used as positive peptide con-
trol stimuli.
IFN-γ Enzyme-Linked Immunospot (ELISPOT) Assay
IFN-γ secretion by HIV-specific cells was quantified by
ELISPOT assay as described [20]. Panels of MHC restricted
stimulating peptides were designed for each study subject
and used to screen responses at each time point tested
(Table 2). Panels were composed of a median of 9 (range
6 to 11 peptides) restricted to a median of 2.5 (range 2 to
5) MHC class I alleles. In addition Gag p17, p24, and p15
peptide pools were also used as stimuli. Cells were plated
at both 2 × 105 cells/well and 5 × 104 cells/well for each
peptide condition. Anti-CD3 monoclonal antibody
(mAb) (Research Diagnostics, Flanders, NJ) and immun-
odominant CMV/EBV derived peptides were used as pos-
itive control stimuli whereas medium was used as a
negative control. The frequency of reactivity of anti-CD3
and EBV/CMV peptides stimuli occurring in longitudi-
nally collected samples was used to control for between-
time point variability in cell responsiveness. Results are
expressed as spot-forming cells (SFCs)/106 PBMC after
subtraction of negative controls. A positive response met
the criteria of having at least 5 spots per well and at least
2-fold more spots than the negative control wells.
Statistical analyses
Data were analyzed by using GraphPad InStat statistical
software, version 3.06 [(2003) GraphPad Software, San
Diego, California, USA]. Two-tailed nonparametric Wil-
coxon matched-pairs signed-ranks tests were used to
assess differences in VL, the magnitude and breadth of
HIV-specific responses, and the percentage of Gag p55-
specific CD4+ and CD8+ T-cells between each TI. Nonpar-
Table 1: Study Population Characteristics
Patient No. MHC Class I Before HAART Intensification Before First Treatment Interruption (TI)
A B C CD4 Cell Count (cells/mm3) CD4 Cell % CD4 Cell Count (cells/mm3) CD4 Cell %
14001 A2/A26 B18/B39 Cw7/Cw12 990 30 1120 33
14002 A2/A1 B60/B51 Cw3/Cw14 330 25 280 25
14003 A1/A3 B7/B8 Cw7/- 650 25 590 27
14004 A2/A3 B38/B44 Cw5/Cw12 400 19 370 22
14005 A3/A69 B35/B44 Cw12/Cw7 230 21 510 27
14006 A1/- B8/B57 Cw6/Cw7 440 23 410 24
14007 A36/A68 B7/B53 Cw4/Cw7 370 16 320 17
14008 A1/A68 B8/B60 Cw3/Cw7 350 14 720 19
14009 A3/A29 B35/B44 Cw4/Cw16 710 37 800 38
14010 A2/A66 B7/B14 Cw7/Cw8 290 24 370 37
Median (range) 476 (230–990) 23.4 (16–37) 549 (280–1120) 25.9 (17–38)Page 3 of 12
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the VL improvements with both increases in the magni-
tude of HIV-specific responses and changes in breadth of
these responses between the 1st and 2nd TI. The total
immune responses generated were expressed as the area
under the curve (AUC) calculated from total HIV-specific
responses over time for each patient. Nonparametric
Spearman rank correlations were used to evaluate the cor-
relation between the total HIV-specific immune responses
and the number of days patients were able to stay off
HAART. All tests for statistical significance were two-tailed
and p values <0.05 were considered significant.
Results
Changes in HIV-specific immune responses
PBMC samples from all time points were screened for
HIV-specific IFN-γ secretion using panels of optimal
epitopes restricted to the MHC class I alleles of the indi-
viduals being tested. These samples were also screened by
IFN-γ ELISPOT assay with Gag peptides pools correspond-
ing to HIV Gag p55. Figure 1 and 2 shows the breadth and
magnitude of the response to the optimal peptide panels
used to screen each individual. The magnitude of the
responses to the HIV peptide panels were compared
before 1, 2 and 3 TIs at time points where subjects were on
HAART in order to assess whether changes in HIV-specific
responses occurred with increasing numbers of TI (Figure
3). For the peptide panel stimuli, the magnitude of the
HIV response increased from 102 ± 137 SFC/106 PBMC at
TI#1 to 559 ± 483 SFC/106 PBMC at TI#2 and 579 ± 688
SFC/106 PBMC at TI#3 (Figure 3A). However, the increase
in the magnitude of the response to peptide panels was
only statistically significant for comparisons between TI#1
and TI#2 (p = 0.016, Wilcoxon matched-pairs signed-
ranks test). For Gag p55 specific responses, a significant
increase in magnitude was seen from TI#1 (336 ± 409
SFC/106 PBMC) to TI#2 (1090 ± 1290 SFC/106 PBMC) (p
= 0.039). No further increase in the magnitude of the HIV
Gag specific response was evident from TI#2 to TI#3 (789
± 1345 SFC/106 PBMC) (Figure 3B). The breadth of the
response to the HIV peptide panels (Figure 3C) also
increased significantly between TI#1 (0.78 ± 0.83 pep-
tides) and TI#2 (2.78 ± 1.99 peptides) (p = 0.031) but did
not increase further at TI#3 (2.22 ± 2.59 peptides).
Table 2: List of MHC class I-restricted peptides used as stimuli
Peptide ID Sequence Location Sequence MHC Restriction (s)
A1-1 p17 (71–79) GSEELRSLY A1
A1-2 Nef (121–128) FPDWQNYT A1
A1-3 Nef (184–192) RFDSRLAFH A1
A2-1 p17 (77–85) SLYNTVATL A2
A2-2 RT (309–317) ILKEPVHGV A2
A2-3/A3-1 Nef (190–198) AFHHVAREL A2, A3
A2-4 p24 (19–27) TLNAWVKVV A2
A2-5 RT (179–187) VIYQYMMDL A2
A2-6 CMV NLVPMVATV A2
A3-2 EBV IVTDFSVIK A3, A11, A6801
B7-1 p24 (47–56) ATPQDLNTML B7, B58
B7-2 p24 (16–24) SPRTLNAWV B7
B7-3/B35-1 Nef (68–77) FPVTPQVPLR B7, B35
B7-4 Nef (128–137) TPGPGVRYPL B7
B7-5 CMV TPRVTGGGAM B7
B7-6 EBV RPPIFIRRL B7
B8-1 p24 (127–135) GEIYKRWII B8
B8-2 Nef (90–97) FLKEKGGL B8
B8-3 p17 (24–31) GGKKKYKL B8
B8-4 RT (18–26) GPKVKQWPL B8
B8-5 p17 (93–101) EIKDTKEAL B8, B60
B8-6 EBV FLRGRAYGL B8
B35-2 RT (175–183) HPDIVIYQY B35
B35-3 gp160 (41–51) GVPVWKEATTT B35
B35-4/B7-7 RT (156–166) SPAIFQSSMTK A3, A3.1, A11, A6801, A33, B7, 
B35
B35-5 Nef (73–82) QVPLRPMTYK A3, A11, A31, B27, B35
B44-1 p24 (174–184) AEQASQDVKNW B44, B57, Cw4
B44-2 p24 (162–172) RDYVDRFYKTL B18, B2601, B44, B70
B44-3 RT (203–212) EELRQHLLRW B44
B44-4 RT (397–406) TWETWWTEYW B44
Cw7-1 gp160 (37–46) TVYYGVPVWK A3, A6801, A11, Cw7Page 4 of 12
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between the study population and individuals in the
chronic phase of infection on continuous HAART that
suppresses viremia to undetectable levels but who do not
undergo therapy intensification, vaccination or TI, nine
historical controls of a similar age and absolute CD4
count to the study population were assembled. The con-
tinuously treated controls were screened with an MHC
class I restricted HIV peptide panel at 2 on-HAART time
points separated by a time interval similar to that between
pre-TI#1 and pre-TI#2 time points in the study population
(p = 0.45; Mann-Whitney test). The size of the peptide
panels used for both the study population and the con-
trols was similar. The magnitude of the IFN-γ responses in
continuously treated controls to the peptide panels tested
did not change significantly from the first to the second
time point tested (data not shown). Furthermore, com-
parison of the magnitude of the change in IFN-γ responses
from the first to the second time point differed signifi-
cantly in these two populations (-240 ± 331 versus +457
± 475 SFC/106 PBMC in the controls and the study popu-
lation, respectively, p = 0.0028; Mann-Whitney test) (Fig-
ure 3D).
In order to determine whether changes in HIV-specific
immunity occurred in the CD4+ or CD8+ cell compart-
ments (or both) we also measured percent of HIV Gag p55
specific IFN-γ secreting CD4+ and CD8+ cells by ICS as
described [31]. Although changes in HIV-specific IFN-γ
secretion responses detected by ICS displayed a similar
trend in both compartments to that observed using the
ELISPOT assay, none of these differences was statistically
significant (not shown).
Timing of appearance and magnitude of HIV-specific 
immune responses with control of VL after HAART is 
withdrawn
The VL plateau decreased 0.44 log10 units from that seen
at TI#1 to TI#2 (p = 0.004, Wilcoxon matched-pairs
signed-ranks test). The average VL decreased 0.48 log10
units from TI#1 to TI#3 (p = 0.055) (Figure 4A). Despite
this, no correlation was evident between VL decrease with
either the increase in the magnitude or the breadth of
HIV-specific immune response to HLA-restricted optimal
peptide panel (Figures 4B and 4C) and Gag p55 peptide
pools (data not shown); VL decrease is defined as the dif-
ference between TI#1 and TI#2 VL plateaus; increase in the
magnitude of HIV-specific immune responses is the differ-
ence in number of SFC/106 PBMC between TI#1 and TI#2
to the peptide panel; increase in breadth of HIV-specific
immune responses is the difference in the number of
epitopes recognized between TI#1 and TI#2.
The participants in this trial spent an average of 50.4% of
the 36 months they were followed after stopping therapy
for the first time off HAART. We therefore investigated
whether there was a correlation between the percentage of
time off HAART and the total HIV-specific immune
responses to either the peptide panel tested or pools of
peptides corresponding to HIV Gag p55. No significant
association between these parameters was observed (not
shown)
Discussion
This report presents results on changes in HIV-specific
immune responses in 10 subjects in the chronic phase of
infection with undetectable HIV VL on HAART at study
entry. All underwent 6 months of therapy intensification
and received an initial dose of the therapeutic vaccine
Remune™ before stopping HAART and all of them
received Remune™ every 3 months for a total of 11 doses.
Treatment was restarted if rebound VL did not decrease to
<50 000 copies within 3 months or if the CD4+ counts
decreased to <200 cells/μl during TI. HAART was again
interrupted when viral load was <50 HIV-1 RNA copies/
ml and CD4+ counts were >200 cells/mm3 on two occa-
sions one month apart.
We found that the average VL plateau decreased signifi-
cantly with TI#1 to TI#2. Although both magnitude of
breadth of immune responses to the screening peptide
panel and Gag p55 peptide pools increased significantly
from TI#1 to TI#2, no correlation between changes in VL
and changes in immune response were detected. Patients
were able stay off HAART for 50.4% of the time over 36
months of follow up. No correlation between the percent-
age of days off HAART and the immune responses gener-
ated was detected.
Subject 14003 was able to maintain viral load to below 40
000 copies/ml after one TI and remained off therapy for
the reminder of the study and was not included in the
analysis (mean VL of 27 288 copies/ml over 968 days).
The VL in subject 14008 remained below 42 000 copies/
ml of plasma (mean VL of 13 937 copies/ml over 637
days) after 2 TIs. This individual was included in compar-
isons between TI#1 and TI#2, but no data was available
for this individual for TI#3. It should be noted that the
absence of statistical significance between the compari-
sons of breadth and magnitude of HIV-specific immune
responses may be related to the small size of comparison
groups.
The increase in the breadth and magnitude of IFN-γ
responses to the peptide panel tested from the time point
prior to TI#1 to the time point prior to TI#2 differs from
the fate of these parameters for HIV-specific responses
observed in chronically infected subjects on continuous
HAART that suppresses VL to below 50 copies/ml of
plasma. First, the magnitude of the IFN-γ responses inPage 5 of 12
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Results of IFN-γ ELISPOT assay for patient 001 to 005Fig re 1
Results of IFN-γ ELISPOT assay for patient 001 to 005. The left y-axis shows the number of spot forming cells (SFC)/
106 PBMC. Each stacked bar shows the number of SFC/106 PBMC generated to the peptide panel tested at each clinic visit. The 
height of the stacks in each the bar represents the number of SFC/106 PBMC induced by each positive stimulus. The height of 
the bar is the cumulative magnitude of the response to the peptide panel tested. The number over the bar is the number of 
peptides in the panel recognized at that time point. The shaded areas are the intervals off HAART. Also shown are viral load 
determinations at each time point keyed to the right y-axis.
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Results of IFN-γ ELISPOT assay for patient 006 to 010. See the legend for Figure 1.
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Comparison of the magnitude and breadth of HIV-specific responses between TI#1, TI#2, and TI#3Figure 3
Comparison of the magnitude and breadth of HIV-specific responses between TI#1, TI#2, and TI#3. A. The 
magnitude of responses to peptide panels increased significantly by a mean of 457 SFC/106 PBMC from TI#1 to the TI#2 (p = 
0.016), and 20 SFC/106 PBMC from the TI#2 to TI#3 (n.s.). B. The magnitude of responses to Gag p55 peptide pools increased 
by a mean of 754 SFC/106 PBMC from the TI#1 to TI#2 (p = 0.039), and decreased by a mean of 302 SFC/106 PBMC from the 
TI#2 to TI#3 (n.s) C. The breadth of responses to the HIV peptide panels used for screening increased significantly by a mean 
of 2.00 peptides from the TI#1 to TI#2 (p = 0.031) and decreased by a mean of 0.56 peptides from the TI#2 to TI#3 (n.s.) D. 
Comparison of the magnitude of the change in IFN-γ responses from the first to the second time point tested in continuously 
treated HIV-infected subjects (controls) and between TI#1 and TI#2 in the study population. The bar in each scatter plot 
shows the mean change in SFC/106 PBMC. The magnitude of the change differed significantly between the controls and the 
study population (-240 ± 331 versus +457 ± 475 SFC/106 PBMC respectively, p = 0.0028; Mann-Whitney test); n.s.= not signif-
icant.
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Correlation between VL and HIV-specific responsesFigure 4
Correlation between VL and HIV-specific responses. A significant reduction of 0.44 log10 unit occurred from TI#1 VL 
plateau to TI#2 VL plateau (p = 0.004) and decreased 0.48 log10 units from TI#1 VL plateau to TI#3 VL plateau (p = 0.055). 
Despite this, no correlation was evident between VL improvement and either the increase in the magnitude or the breadth of 
HIV-specific immune response; VL improvement is the difference between the TI#1 and TI#2 VL plateau; increase in the mag-
nitude is the difference in SFCs between TI#1 and TI#2; increase in breadth is the difference in the number of epitopes recog-
nized between TI#1 and TI#2.
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from the first to second time tested and the change in
magnitude of IFN-γ responses from the first to the second
time point differed significantly in these two populations.
This supports the conclusion that the study population
interventions including treatment intensification, vacci-
nation and TI led to expansion of HIV-specific immunity.
Several factors may account for the lack of correlation
between the increase in the magnitude and breadth of
HIV-specific immune responses measured by IFN-γ ELIS-
POT and VL decrease from TI#1 to TI#2. First, the use of
optimal peptide panels and Gag peptide pools corre-
sponding to reference strain HIV isolates rather than
autologous sequences may underestimate the true extent
of HIV specific immunity [32]. Although the same set of
stimuli were used to assess HIV-specific IFN-γ secretion at
all time points, it is possible that the accumulation of viral
sequences changes no longer recognized by HIV-specific
cells with time reduces the correlation between this func-
tion of HIV-specific cells and VL control.
Second, the cytolytic activity of CD8+ T-cells is believed to
be important in controlling the viral burden in HIV infec-
tion. Since IFN-γ secretion has been shown to be a surro-
gate for the level of CD8+ T-cell effector activity, IFN-γ
ELISPOT and ICS are the standard techniques used to
screen for antigen specific CTL [33]. However, recent stud-
ies have shown that lysosomal-associated membrane pro-
tein-1 (LAMP-1 or CD107a) expression on the cell surface
could be a better marker for CD8+ T-cell cytolysis.
CD107a has been shown to be upregulated following
antigenic stimulation coupled with degranulation and the
release of perforin [34,35]. Moreover, studies in chronic
viral infection in murine models have shown that there is
a hierarchical exhaustion of CD8+ T-cell functions. Virus-
specific memory CD8+ T-cells progressively loose their
functional capabilities in response to viral antigen recog-
nition starting with the inability to secrete interleukin-2
(IL-2), and reduced proliferative and lytic activity. Next,
the ability to secrete tumor-necrosis factor alpha (TNF-α)
wanes [36]. IFN-γ secretion is the CD8+ T cell function
most resistant to exhaustion. Therefore, the measurement
of HIV-specific IFN-γ-secreting CD8+ T-cells might reflect
an incomplete picture of HIV-specific immune responses
best associated with suppression of viral replication.
As well, recent reports have shown that the breadth and
magnitude of HIV-specific IFN-γ responses to all
expressed HIV genes do not correlate with either VL or
with rate of CD4+ T cell decline [37,38]. While it is fairly
well established that HIV-specific CD8+ cells do mediate
anti-viral activity, it may be that other functions of these
cells correlate better with control of HIV replication than
IFN-γ secretion. Studies with HIV infected long-term non-
progressors (LTNPs) showed that they have elevated HIV-
specific proliferative capacity coupled to increased per-
forin expression when compared to HIV infected disease
progressors [15]. Moreover, LTNPs possess an enhanced
CD8 T-cell functional profile compared with progressors
including maintenance of polyfunctional responses such
as TNF-α and IL-2 secretion in addition to other functions
[39]. Furthermore, aviremic patients treated during pri-
mary infection have increased HIV proliferative capacity
as well as ability to maintain an HIV-specific IL-2-secret-
ing CD4+ T-cell population when compared to viremic
patients [40]. These studies suggest that it is the quality
(HIV-specific IL-2 secretion and proliferation in particu-
lar), rather than the quantity of HIV-specific responses
that may be better immune correlates of viral control.
Conclusion
In summary our study showed that HAART intensification
with GM-CSF, ddI and HU followed by Remune™ vaccina-
tion augmented HIV-specific IFN-γ secretion from TI#1 to
T1#2 with a corresponding significant decrease in VL.
However, no correlation could be established between
these two phenomena. Patients were able to stay off
HAART for 50.4% of the period of the study. TIs are an
important part of the clinical management of HIV
infected subjects because of the potential cost saving,
reversion of drug-resistant virus to drug sensitive variants,
and patients' request for a break from their medications.
Therefore, the immunological and virological benefits
observed in this proof of concept study warrant further
studies with a larger patient population to identify poten-
tial protective HIV-specific immune responses induced by
this therapeutic strategy of TI in combination with
Remune™ vaccination. In addition, recent studies with
Remune vaccination in chronic HIV-infected patients
showed an induction of polyfunctional HIV-specific
CD8+ T-cells with increased proliferative capacity, IL-2,
MIP-1β, IFN-γ, and TNF-α secretion [41]. Thus, future
immune monitoring for T-cell responses vaccine trials
should include not only IFN-γ secretion, but also poly-
chromatic flow cytometry to assess proliferation, degran-
ulation, other cytokine and chemokine secretion as well.
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